In addition, nilotinib (AMN107, Tasigna), another TK inhibitor used in the treatment of BCR-ABL-positive chronic myelogenous leukaemia, also transported by ABCB1, ABCC10 and ABCG2, significantly enhanced the cytotoxicity of colchicine, vinblastine and paclitaxel in KB-C2 and KB-V1 cells, showing that the combination of different anticancer agents is likely to have an additional synergistic beneficial effect [117]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.